LY 2606368 is primarily utilized in the field of cancer research due to its role as a checkpoint kinase 1 (CHK1) inhibitor. It is being studied for its potential to enhance the efficacy of DNA-damaging chemotherapeutic agents by preventing cancer cells from repairing DNA damage, thereby promoting cell death. This compound is particularly relevant in the treatment of solid tumors and hematologic malignancies, where it may help overcome resistance to conventional therapies. Additionally, LY 2606368 is being explored in preclinical and clinical trials to evaluate its safety, tolerability, and effectiveness as part of combination therapies. Its ability to target CHK1 makes it a promising candidate for advancing personalized medicine approaches in oncology.